{"ticker": {"uuid": "c4fb3871-7de2-4abc-82f9-b8d920f70ec7", "symbol": "TXG", "name": "10X Genomics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Health Information Services"}, "articles": [{"title": "10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/10x-genomics-report-second-quarter-200500108.html", "source_name": "PR Newswire", "published_at": "2026-07-15T20:05:00+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics sets Aug. 6 webcast to discuss second-quarter results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYVlYdktGMHpFbUtQZmxBVzBKa29WM01La2JzM284eGFoWEluaFN6MFI0eW8xZUZxWEhlRURHRDV6WTVSdVdmWG8zVlBEN1dad1AzNHdveHRvOGctbFJGWFRQM25QSzBFWGlfdUw1emwzQmI2WUdCdTd0YUhDdVNWTkt2V01uV0RXWGMyU3lmMkFSQ2N6RC1PU25kTlJlazVNdEM1ZDYySm1NX2Myc0c2WjFGWENHYVdS?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:05:00+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics, Inc. Stock 12\u2011Month Price Target Raised to $35.46, Implies 17% Downside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQVHBKM1U0VzFEZlFBd0JiQjduSGI3R2c0Nmlxb1g5cTg0RURraDM1b0xYR1FzQnZBdDdXdW9OWmZaeWFXTHVYYlhoZWRhQlNrTFB5Q25CN0dvTldmc2VURFdNdHU3cHptSF9uWkhrUi1IYnNpbmZDTk11N3lRR0Nkbm5rUXhIMFRDeTdtSGJBa1hxdXdZdVg0bnViWGwwazJyRFJFQkZHYlVGd21HTWpnbjB4LVFFU0c5Y2ctbXIwRlZXTW1wWm9VS0dWMWlBMUpOZTFRQmRwVXhEdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T16:20:05+00:00", "published_display": "13 Jul 2026 16:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Adjusts 10x Genomics Price Target to $46 From $30", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-securities-adjusts-10x-genomics-153619470.html", "source_name": "MT Newswires", "published_at": "2026-07-13T15:36:19+00:00", "published_display": "13 Jul 2026 15:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does 10x Genomics (TXG) Leaving Russell Value Indexes Reframe Its Growth Versus Profitability Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPYl8xcjh4eG1YS3FMel9tTkNTMWFuZk54cEo0U3M5ekUxM2hMWmtlYTZJcWJhNHA2Vk4weXhkVG1RYy1ITHdTYzF1enl4Mk9FdktBbnZPaVc3TFVva0VrNUZtbnVuM3A2VFl5QXAxMXZYSEI1M21DaTFuU1Y5QnNuZUg1VUhnZ0w5eUZuaHZzWmwyeXl1MVpkVWpB?oc=5", "source_name": "Market source", "published_at": "2026-07-10T04:32:00+00:00", "published_display": "10 Jul 2026 04:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is 10x Genomics (TXG) Overvalued Following Its Earnings Beat?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNSU5UaGE1NktDcThvN2NzME5HRFRaeHhhS1VMdUdjUnlpRkFYS3VuUGZ6cnA3UkxqMWlmaE92cHJHRkpJUWpqX2YtS0p5eHBmVHFyR3lKUjY5ZWxybzU1aEFtUldlWVM4cjdOU09Md052eTYxMGgtRGI4TVlsS0dSZkI3dUgwWVhQajdGdGpNZVk5aDE3dHNVeTNHb2V6c09ianpjMg?oc=5", "source_name": "Market source", "published_at": "2026-07-09T16:11:14+00:00", "published_display": "09 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TXG Stock Climbs As Wall Street Hikes Price Targets", "summary": "10x Genomics Inc. (TXG) stock has surged over 12% following positive analyst coverage and strategic company developments. Barclays and Citi both raised their price targets for TXG, citing improving sentiment in life science tools and the potential for earnings growth. Key drivers", "url": "https://stockstotrade.com/news/10x-genomics-inc-txg-news-2026_07_09/", "source_name": "StocksToTrade", "published_at": "2026-07-09T16:58:22", "published_display": "09 Jul 2026 16:58", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Stock Looks Reasonable On Cash Flow But Rich On Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPWWR6ZVNsT2ZlNnN1VDVtNjZELWo3eG1VRUpjcG55Sm5YQ1pCS0U1b0lXS2x4VXVFVlNMVHdtM1k2SU9GeHhYd0xQVjBEU3c1QmRuRk5MR0diSzZSaEo1YXFSMVZSdGlmSUVkWGFLZlFOUHBnb1ZvaXM0b0dWY2ZfY2NtR3VKRHpoUTEyREtNa2c0QldPd2xqcA?oc=5", "source_name": "Market source", "published_at": "2026-07-09T09:11:24+00:00", "published_display": "09 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/life-sciences-tools-services-stocks-152244491.html", "source_name": "StockStory", "published_at": "2026-07-08T15:22:44+00:00", "published_display": "08 Jul 2026 15:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of 10x Genomics Inc Class A \u2013 SWB:1KJ", "summary": "This article provides the forward price-to-sales ratio for 10x Genomics Inc Class A (SWB:1KJ) listed on the Stuttgart Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content emphasizes financial data and market specifics for this biot", "url": "https://www.tradingview.com/symbols/SWB-1KJ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T20:40:57", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in 10x Genomics Inc Class A Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A stocks. It provides detailed financial information for each ETF, including market value, weight of the stock in the fund, issuer, management style, expense ratio, assets under management (A", "url": "https://www.tradingview.com/symbols/LSE-0A88/etfs/", "source_name": "TradingView", "published_at": "2026-07-07T10:40:57", "published_display": "07 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1KJ Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for 10x Genomics Inc Class A (1KJ) stock, based on analyst opinions. It includes details on price estimates, historical highs and lows, upcoming earnings reports, and financial metrics such as EPS, revenue, net income, and EBITDA.", "url": "https://www.tradingview.com/symbols/TRADEGATE-1KJ/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-05T09:44:24", "published_display": "05 Jul 2026 09:44", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does 10x Genomics' (TXG) Russell Value Index Exit Reveal About Its Evolving Investor Base?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Leaves Russell Value Indexes, Is The Rally Already Priced In?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10X GENOMICS INC-CLASS A (TXG) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE5zYmszUnRtTXZCU25ELTFpMjBQekd4UXBWS0FkRjZyZmZFRkRfLWxHOEJJd2x4QTNORVhVU1Zic0I0YlQtT1lMRkhzLThLWG9CZ002UVRpcDlNN0lOZWFUbVNPNA?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:09:11+00:00", "published_display": "03 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ)", "summary": "This article provides an overview of 10x Genomics Inc Class A (FWB:1KJ) stock, including financial actuals and estimates, analyst forecasts, and company financial details. It covers stock price history, earnings, revenue, net income, lack of dividends, employee count, and EBITDA.", "url": "https://www.tradingview.com/symbols/FWB-1KJ/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-28T09:40:54", "published_display": "28 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ)", "summary": "This article provides financial actuals and estimates for 10x Genomics Inc Class A (1KJ) on the Dusseldorf Stock Exchange. It includes analyst opinions on future price targets, historical stock performance, earnings reports, revenue, net income, and employee information. The comp", "url": "https://www.tradingview.com/symbols/DUS-1KJ/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T14:09:35", "published_display": "27 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ)", "summary": "This article provides financial actuals and estimates for 10x Genomics Inc Class A (MUN:1KJ), including income statement, balance sheet, and cash flow data. It covers analyst forecasts, historical price performance, upcoming earnings dates, recent earnings per share and revenue f", "url": "https://www.tradingview.com/symbols/MUN-1KJ/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T11:39:51", "published_display": "26 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of 10x Genomics Inc Class A \u2013 LSE:0A88", "summary": "This article provides financial information for 10x Genomics Inc Class A (LSE:0A88), focusing on its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showcasing the company's financial metrics and data sources.", "url": "https://www.tradingview.com/symbols/LSE-0A88/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:51", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG)", "summary": "This article provides current and historical financial data and analyst estimates for 10x Genomics, Inc. (NASDAQ:TXG). It covers stock price performance, forecasts, market capitalization, earnings, revenue, and other key financial metrics. The company's next earnings report is an", "url": "https://www.tradingview.com/symbols/NASDAQ-TXG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:41:03", "published_display": "26 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of 10x Genomics Inc Class A \u2013 LSE:0A88", "summary": "This article provides the \"Price to sales forward\" metric for 10x Genomics Inc Class A (LSE:0A88). It is a standalone financiero data point without additional analysis or context within the provided content. The relevant financial information is presented as \"Period Value Change ", "url": "https://www.tradingview.com/symbols/LSE-0A88/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:11:10", "published_display": "25 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of 10x Genomics Inc Class A \u2013 LSE:0A88", "summary": "This page from TradingView displays financial information for 10x Genomics Inc Class A (LSE:0A88), specifically focusing on its forward price-to-earnings ratio. The content indicates that while the company's stock is listed on the London Stock Exchange, the market was closed at t", "url": "https://www.tradingview.com/symbols/LSE-0A88/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:11:15", "published_display": "25 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com", "summary": "Serge Saxonov, CEO of 10x Genomics, sold 29,900 shares of company stock for over $1 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock was trading near its 52-week high after a significant gain. The company's stock is currently conside", "url": "https://ng.investing.com/news/stock-market-news/10x-genomics-ceo-serge-saxonov-sells-103m-in-stock-93CH-2573196", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T04:11:10", "published_display": "25 Jun 2026 04:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics CEO Serge Saxonov sells $1.03m in stock", "summary": "Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 29,900 shares of Class A Common Stock worth approximately $1.03 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock traded near its 52-week high, and Mr. Saxonov still holds si", "url": "https://m.uk.investing.com/news/stock-market-news/10x-genomics-ceo-serge-saxonov-sells-103m-in-stock-93CH-4743524?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T03:11:15", "published_display": "25 Jun 2026 03:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan", "summary": "10x Genomics (TXG) CEO Serge Saxonov sold 30,000 shares of Class A common stock on June 22, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales, totaling over $1 million, occurred at weighted average prices between $33 and $36 per share. After ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-537517dfca91.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:09:21", "published_display": "24 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is 10x Genomics (TXG) Stock Soaring Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNcGV3X3EwdllIS0p4cjkzRUYzY3IxTm9VaTd3dTFCY2MzTHBwNm1aVlZiR2tNajZrVzE3THRpdU9iVXZXNVlaeVBYSGtxZ1pmdmdVZHR4NWJsYjhmZWlETTFDUXU2QlZHZjBWYlFMRjJMaS1ib2lpUEItclZ0aVQ2NEdsMHlrNFI4T2VUM2VLSlFEZTdhcEE?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 10X Genomics Inc For: 24 June By Investing.com", "summary": "This article reports on the filing of Form 4 by 10X Genomics Inc. for June 24, as published by Investing.com. It is a brief announcement without further details on the content of the Form 4 filing.", "url": "https://in.investing.com/news/stock-market-news/form-4-10x-genomics-inc-for-24-june-93CH-5469683", "source_name": "Investing.com India", "published_at": "2026-06-23T21:40:57", "published_display": "23 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TXG - 10x Genomics Inc Stock Price and Quote", "summary": "This article provides a detailed stock overview for 10x Genomics Inc (TXG), including its current stock price, financial metrics, analyst ratings, and recent news. It also lists insider transactions, highlighting sales by key executives. The company is involved in life science te", "url": "https://finviz.com/stock?t=TXG", "source_name": "Finviz", "published_at": "2026-06-19T15:11:05", "published_display": "19 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades", "summary": "10x Genomics, Inc. director Shehnaaz Suliman sold a total of 5,723 shares of Class A Common Stock in open-market transactions on June 16, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, at weighted average prices of $32.5890 ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-d2742e1c3306.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:39:33", "published_display": "18 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOS0xkRjIzR2FQaTFQTDlrems1TElfRE5lM0VVclZybjBzSmMzNnkyRWlkOENFUlEzT2pGVzRIZkFkRWtUNHB0UVVLN3p4VWlZUUwtZDFHTGRTZG53QUU4SW4xSHBPbS1xMFVRSDlTdEZxbTdzeThkVWJhZzh0NlNDQi11SEQ4WHhCNEYzYjlxblVzekJKbjh5WHNkWEd6WGZELURSclF0NlNlcmR2TXpCRw?oc=5", "source_name": "TradingView", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Launches Cleveland Clinic Partnership For Bladder Cancer Diagnostics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary", "summary": "TXG (10x Genomics, Inc.) has filed a Form 144 notice detailing proposed sales of Class A Common stock related to multiple RSU vesting events, with JP Morgan Securities LLC identified as an intermediary. The filing specifies various vesting dates between August 2021 and August 202", "url": "https://www.stocktitan.net/sec-filings/TXG/144-10x-genomics-inc-sec-filing-fce261db42c2.html", "source_name": "Stock Titan", "published_at": "2026-06-16T23:58:57", "published_display": "16 Jun 2026 23:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider 10x Genomics (TXG) After Its Recent 187% Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOM0FUcVFpekFRY0E5VWVVZmdwNGU3T1FJdEh1WElYQ2Z6TTJ4aVl2OUR4Nm1ObDJZbjlDTkRUeWpFVzhXTlhxN0kySGdoNm53dGR5QXpiR1JyX2c5YlhjT3NiQjRNa1V5RmZYN0hMamRxRlVxVFZTOVdRQm11MEo5Qmw5NmpBbW5XUUxwc2FEQ1A0eC02Vm42NTZn?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group", "summary": "10x Genomics has acquired Proteintech Genomics, a division specializing in high-plex proteomic solutions for single cell and spatial applications on 10x platforms. This acquisition expands 10x Genomics' capabilities in proteomics and supports its vision for integrating transcript", "url": "https://www.morningstar.com/news/pr-newswire/20260609la79033/10x-genomics-acquires-proteintech-genomics-a-division-within-proteintech-group", "source_name": "Morningstar", "published_at": "2026-06-09T13:00:00", "published_display": "09 Jun 2026 13:00", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) awards 8,829 RSUs to company director", "summary": "10x Genomics director Sarah A. Teichmann was awarded 8,829 restricted stock units (RSUs) of Class A Common Stock. These RSUs were granted at no cash cost and increased her direct holdings to 35,609 shares. The RSUs will vest in quarterly installments, with one-quarter vesting on ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-4368fc47e83d.html", "source_name": "Stock Titan", "published_at": "2026-06-09T09:39:35", "published_display": "09 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs", "summary": "10x Genomics (TXG) director Kimberly J. Popovits was granted 8,829 Restricted Stock Units (RSUs) as an equity award, increasing her direct holdings to 37,445 shares. These RSUs will vest quarterly, starting May 21, 2026, contingent on her continued service. The grant is classifie", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-34557a290421.html", "source_name": "Stock Titan", "published_at": "2026-06-09T09:39:35", "published_display": "09 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) awards 8,829 RSUs to board director", "summary": "10x Genomics director, John R. Stuelpnagel, was granted 8,829 restricted stock units (RSUs). These RSUs will vest in four equal quarterly installments starting May 21, 2026, provided he remains a service provider. Following this grant, Stuelpnagel holds 368,436 shares of Class A ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-4db925ed113a.html", "source_name": "Stock Titan", "published_at": "2026-06-09T09:39:35", "published_display": "09 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) director receives 8,829 RSUs vesting from 2026", "summary": "10x Genomics director Alan Mateo has been granted 8,829 restricted stock units (RSUs) for Class A Common Stock. These RSUs will vest in four equal quarterly installments starting May 21, 2026, contingent upon his continued service. Following this grant, Mateo's direct holdings in", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-04a2f5fbfe19.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:39:35", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings", "summary": "Sridhar Kosaraju, a director at 10x Genomics (TXG), was granted 8,829 Restricted Stock Units (RSUs) as part of a stock-based compensation award. This grant increases his direct holdings to 65,278 shares, with an additional 3,000 shares held indirectly through a family trust. The ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-7fbd5afbd7c6.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:39:35", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman", "summary": "10x Genomics director Shehnaaz Suliman has been granted 8,829 restricted stock units (RSUs) of Class A Common Stock, as reported in a recent Form 4 filing. This equity award, which has no cash purchase price, increases her direct holdings to 37,445 shares. The RSUs will vest in f", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-0d3f6f0ee1e1.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:39:35", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda", "summary": "10x Genomics (NASDAQ: TXG) shareholders approved all proposals at their 2026 annual meeting, including the election of three Class I directors for three-year terms, the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, an", "url": "https://www.stocktitan.net/sec-filings/TXG/8-k-10x-genomics-inc-reports-material-event-1af1ef2dbb13.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:46:32", "published_display": "08 Jun 2026 20:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Stock On Fire: Up 36% With 7-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPU0ZiOWxUVjdwa2pMM3ZwQzZPdE9lRmlSeTRSSlZoU3dqbVFDMmVEX3JyQnJNOUJERUxuQWIwSkQ5SENqNTRfRTJyejNzcXE1bTJNdXFsZ3FiUUdNNExZNHZya3k5X2h0cnNKdlRHVm53NVBDMFI3X2dGc1MxUWxZNHhJNWpXM0ZDQWNWZUtDWW5sMGlzb2QwWkcyTTlMRXhXaWVTakhWdU1zVVhnQlBlUXNaOVp2OFI1Mnc?oc=5", "source_name": "Trefis", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics CEO Serge Saxonov sells $709,057 in shares", "summary": "Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales, conducted between $24.4415 and $24.7092 per share, included shares sold to cover tax obligations and those executed via ", "url": "https://www.investing.com/news/insider-trading-news/10x-genomics-ceo-serge-saxonov-sells-709057-in-shares-93CH-4713355", "source_name": "Investing.com", "published_at": "2026-05-30T08:10:53", "published_display": "30 May 2026 08:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics CEO Serge Saxonov sells $709,057 in shares By Investing.com", "summary": "Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales were related to tax obligations from restricted stock units and a pre-arranged trading plan. Despite his sales, Saxonov r", "url": "https://ng.investing.com/news/insider-trading-news/10x-genomics-ceo-serge-saxonov-sells-709057-in-shares-93CH-2532354", "source_name": "Investing.com Nigeria", "published_at": "2026-05-28T22:39:37", "published_display": "28 May 2026 22:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics president Hindson sells $283,399 in company stock By Investing.com", "summary": "10x Genomics President and Chief Scientific Officer, Benjamin J. Hindson, sold 11,595 shares of company stock totaling $283,399 to cover tax obligations. This sale occurred while TXG stock was trading near its 52-week high after a significant 197% gain, though it appears overvalu", "url": "https://au.investing.com/news/insider-trading-news/10x-genomics-president-hindson-sells-283399-in-company-stock-93CH-4459010", "source_name": "Investing.com Australia", "published_at": "2026-05-28T08:02:00", "published_display": "28 May 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess 10x Genomics (TXG) After Its 188% One Year Share Price Surge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNdFB6OWxld3B1ZnNPTkVqRzNUem9zS0o1THlyZ1A2OVVhYjEzY0lTMjdQdkFIcGxxT0FoY21xLTVWamsyRXBycG1EbkJzWERBV1pnRDA1b2tPUVZqWmRESGp0b1VBWTFDUzVzT3d3SVZzNVJNakd1MlFqSXIzSDU1UE9n?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At 10x Genomics (TXG) Valuation After A Strong Year And Recent Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZWcwc0ZhY2pRc25US0I1XzNLWi1GQ0lJN3BEdWZHd2k2ZTJxbWMtOF9FQ0t2MThjMERCNXRkTUc0VlFOa0tmYjVaYmZWMVBZdmtYNlBwUjYySE9LYnNKX2ZtWkFuRDZpRk9mWjNBUERaTnJyX05yOTBXRFlRbGNsRllRbnV0LTJQWC1UZ0dmU2tLek90MDlHcUNVZWE?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why 10x Genomics (TXG) Stock Is Down Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNVGVkaDZ2emhIXzdrM1ZLRDBHYjhqV3d2ZUNYcUxVUFpDcDEwUTBJV2Y5dWtRSnhIRmxiYXhiSTlVYzVFczRsWDdhblh4TmRZYkVGX3RKQVJ4X252Wl9OMEtxZTNBbmRJLXh0V1NMa3NpNWYzOHA5NHFnaHUyWlk0aHRKLWdQTGhLeTRSZy1kTzFSVEFGRTdVbW84ampxcUlZLUFR?oc=5", "source_name": "StockStory", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Loss Reduction To US$0.35 TTM EPS Challenges Bearish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOWGxlcFNXa2ZTaE5DVm9IMGo1VFdPN2tCTHU1YkVKV3NmQWVUMkZnZnc1bFZHZHBGVE8tZVhkYWpNek9EbHBydGZHWk55YnBFU25QTU1sd1VnQVBJdnpwaUo4MlVpaFAyd2g1NVk1NWk2cjlFLWNWck5VbVpOUU80Uld4NjdLQ3REQm1JTjl1QnZWeWFCN1FhX3pEdmZGSHZDc2MxZUtsejJiek9SNnJiU2NUYw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPN1NiQzVablpIaENaM3ZTdEVLTi1ZYnlUeTZNNm1kQVpTa3VMS3dqX1dzSXlZNVBfUXA2NlZqaEZOREpVNWJLS05iX1pGWlRDMFMwNW1DQVlLSmk1TXJJaDh3c2FfQzV6UXFXT3IyajdJSVNrMm02SzBUZGtNdWdTakxvbFVJRVY5bmFJYWtMTFFzYlIxcFd2RnJuTQ?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Stock Falls 5.4% After Thermo Fisher Q1 Miss Signals Life Sciences Slowdown - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNVklBLVYtY2J2QXlHTlpLSm9ZdHRpOWVsSHlVeFNUeEVobHQ1TmFibW1DRU83UHczclozQ2wtOEVMOE4wLTl4UFZGMEFJbDNsX1haRTUxLWRMc3FDRm9RZ2syaXR1NS1IdDdSeC1ma1JaOUg4eW15VFRkemNHS2NXcjQ2OFplWXVYZ25MdnYyYTdzZThTdHc?oc=5", "source_name": "IndexBox", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 6, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why 10x Genomics (TXG) Shares Are Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQOS1EUXFGeThJbTNvcmEtRS1GRjBJTGhuMGx2QmhXbFdtRmZjbUduQVktR2MxSTZjaE9TMGVIX1VfOFh6SGM1SUVGenZGQ0F3OXZiV3kzaWRzOWV1VExydFF2cjJuOVVDX3I5Sm9mQnY0M3JjdVVXYlJGUWNMRXcwalNFR21TLVVnNy0tSlBCSU5IUVhuUHB3?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Launches Atera: A Breakthrough in Spatial Bio", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOQjkwRWxrODdYelF1RnY1TXJyb3JFTUozc0o3ai11NkQtNHBma1N6U1dNUzdDVU55dk9sRjRpSjZHaVdZUWhVMXlzamJ3cmZBNGlNaDFtMER3cHR3VWxFUFhCbEkzbl9RajBjRU4yYnRrWXJMWXUwTDlyeHVGTGhKM3dTRnJCdzl6bFlqbEVuQWdSTm9RSmZvUE5UcE5PaGtySmVFaVdHWQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Overvalued Tech Stocks? Texas Instruments, Jabil, 10x Genomics Face Scrutiny - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPVXB0SGxNbVZpblAxMjY0YUIzMlBVUU1YdFFPTGRZdHFQaWt4NUtrRnY1VVI5TWtMdUppZjcwTXFBVTZ2YnF5c1hOZEpoVGJicE5yenRUU3FlMTZKeERpQUstNFlja3RxVzRQTzdKZGVNVGpHS0Y1TlphOUI1UUEwYUxRWk1KV2hKclJteHI4MVNFaEdn?oc=5", "source_name": "IndexBox", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioptimus launches spatial biology atlas with 10x Genomics", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPWmFtWjY4YXFoM29icnV5YXdBSzB3YVdmc1E5bmI0T3k1U19oR1FVSzNzWlNQYmJFOGtEaC1HVUx6dnlIMjBkOU1kNS1aZGlqY0puSDl6ZnhTd25VS2JjSTUwbktTLWE2MFBrWHYyTzcxX204X0IydnN3NXNUQnEyN3owYW9KQ1luU3dWQ2NEbkhiSmthY05CdFoza1l2djkzeWJoVlpBWmFUNGVOTWRoV3JoMGxtZw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNZXpuV2xhcENqNm1FS00xSXAxUGRTUm9mTEs0OGFvLVhaWHdWQmZPTlltTkQ2QUlnVDRRbG5fa0ZIa20wZW9HZi1haTZ2YU9NWlJDaFBxYWtkOTdqLTk3Z1AtV1RhVmdEczFfbDNXSXgwRlg4NWM0X09DaS0ta3NnMUNKYk5SVUtuX0d0bWVfeTRzVGFmUnUzSDNlTDJuanlzVHBsMnJFUi1BUmw5UTdqWFh6ME4xR1lZUGJBS0QtbU94Y2NqVjhCSjJqTjRraVJDdldPUDcxQThiNk5XYUpITzl2SGtuYk0yOG91TDJ1NA?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/10x-genomics-report-second-quarter-200500108.html", "source_name": "PR Newswire", "published_at": "2026-07-15T20:05:00+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics sets Aug. 6 webcast to discuss second-quarter results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYVlYdktGMHpFbUtQZmxBVzBKa29WM01La2JzM284eGFoWEluaFN6MFI0eW8xZUZxWEhlRURHRDV6WTVSdVdmWG8zVlBEN1dad1AzNHdveHRvOGctbFJGWFRQM25QSzBFWGlfdUw1emwzQmI2WUdCdTd0YUhDdVNWTkt2V01uV0RXWGMyU3lmMkFSQ2N6RC1PU25kTlJlazVNdEM1ZDYySm1NX2Myc0c2WjFGWENHYVdS?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:05:00+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics, Inc. Stock 12\u2011Month Price Target Raised to $35.46, Implies 17% Downside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQVHBKM1U0VzFEZlFBd0JiQjduSGI3R2c0Nmlxb1g5cTg0RURraDM1b0xYR1FzQnZBdDdXdW9OWmZaeWFXTHVYYlhoZWRhQlNrTFB5Q25CN0dvTldmc2VURFdNdHU3cHptSF9uWkhrUi1IYnNpbmZDTk11N3lRR0Nkbm5rUXhIMFRDeTdtSGJBa1hxdXdZdVg0bnViWGwwazJyRFJFQkZHYlVGd21HTWpnbjB4LVFFU0c5Y2ctbXIwRlZXTW1wWm9VS0dWMWlBMUpOZTFRQmRwVXhEdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T16:20:05+00:00", "published_display": "13 Jul 2026 16:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Adjusts 10x Genomics Price Target to $46 From $30", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-securities-adjusts-10x-genomics-153619470.html", "source_name": "MT Newswires", "published_at": "2026-07-13T15:36:19+00:00", "published_display": "13 Jul 2026 15:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does 10x Genomics (TXG) Leaving Russell Value Indexes Reframe Its Growth Versus Profitability Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPYl8xcjh4eG1YS3FMel9tTkNTMWFuZk54cEo0U3M5ekUxM2hMWmtlYTZJcWJhNHA2Vk4weXhkVG1RYy1ITHdTYzF1enl4Mk9FdktBbnZPaVc3TFVva0VrNUZtbnVuM3A2VFl5QXAxMXZYSEI1M21DaTFuU1Y5QnNuZUg1VUhnZ0w5eUZuaHZzWmwyeXl1MVpkVWpB?oc=5", "source_name": "Market source", "published_at": "2026-07-10T04:32:00+00:00", "published_display": "10 Jul 2026 04:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is 10x Genomics (TXG) Overvalued Following Its Earnings Beat?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNSU5UaGE1NktDcThvN2NzME5HRFRaeHhhS1VMdUdjUnlpRkFYS3VuUGZ6cnA3UkxqMWlmaE92cHJHRkpJUWpqX2YtS0p5eHBmVHFyR3lKUjY5ZWxybzU1aEFtUldlWVM4cjdOU09Md052eTYxMGgtRGI4TVlsS0dSZkI3dUgwWVhQajdGdGpNZVk5aDE3dHNVeTNHb2V6c09ianpjMg?oc=5", "source_name": "Market source", "published_at": "2026-07-09T16:11:14+00:00", "published_display": "09 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TXG Stock Climbs As Wall Street Hikes Price Targets", "summary": "10x Genomics Inc. (TXG) stock has surged over 12% following positive analyst coverage and strategic company developments. Barclays and Citi both raised their price targets for TXG, citing improving sentiment in life science tools and the potential for earnings growth. Key drivers", "url": "https://stockstotrade.com/news/10x-genomics-inc-txg-news-2026_07_09/", "source_name": "StocksToTrade", "published_at": "2026-07-09T16:58:22", "published_display": "09 Jul 2026 16:58", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Stock Looks Reasonable On Cash Flow But Rich On Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPWWR6ZVNsT2ZlNnN1VDVtNjZELWo3eG1VRUpjcG55Sm5YQ1pCS0U1b0lXS2x4VXVFVlNMVHdtM1k2SU9GeHhYd0xQVjBEU3c1QmRuRk5MR0diSzZSaEo1YXFSMVZSdGlmSUVkWGFLZlFOUHBnb1ZvaXM0b0dWY2ZfY2NtR3VKRHpoUTEyREtNa2c0QldPd2xqcA?oc=5", "source_name": "Market source", "published_at": "2026-07-09T09:11:24+00:00", "published_display": "09 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/life-sciences-tools-services-stocks-152244491.html", "source_name": "StockStory", "published_at": "2026-07-08T15:22:44+00:00", "published_display": "08 Jul 2026 15:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of 10x Genomics Inc Class A \u2013 SWB:1KJ", "summary": "This article provides the forward price-to-sales ratio for 10x Genomics Inc Class A (SWB:1KJ) listed on the Stuttgart Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content emphasizes financial data and market specifics for this biot", "url": "https://www.tradingview.com/symbols/SWB-1KJ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T20:40:57", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in 10x Genomics Inc Class A Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A stocks. It provides detailed financial information for each ETF, including market value, weight of the stock in the fund, issuer, management style, expense ratio, assets under management (A", "url": "https://www.tradingview.com/symbols/LSE-0A88/etfs/", "source_name": "TradingView", "published_at": "2026-07-07T10:40:57", "published_display": "07 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1KJ Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for 10x Genomics Inc Class A (1KJ) stock, based on analyst opinions. It includes details on price estimates, historical highs and lows, upcoming earnings reports, and financial metrics such as EPS, revenue, net income, and EBITDA.", "url": "https://www.tradingview.com/symbols/TRADEGATE-1KJ/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-05T09:44:24", "published_display": "05 Jul 2026 09:44", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does 10x Genomics' (TXG) Russell Value Index Exit Reveal About Its Evolving Investor Base?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Leaves Russell Value Indexes, Is The Rally Already Priced In?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10X GENOMICS INC-CLASS A (TXG) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE5zYmszUnRtTXZCU25ELTFpMjBQekd4UXBWS0FkRjZyZmZFRkRfLWxHOEJJd2x4QTNORVhVU1Zic0I0YlQtT1lMRkhzLThLWG9CZ002UVRpcDlNN0lOZWFUbVNPNA?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:09:11+00:00", "published_display": "03 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ)", "summary": "This article provides an overview of 10x Genomics Inc Class A (FWB:1KJ) stock, including financial actuals and estimates, analyst forecasts, and company financial details. It covers stock price history, earnings, revenue, net income, lack of dividends, employee count, and EBITDA.", "url": "https://www.tradingview.com/symbols/FWB-1KJ/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-28T09:40:54", "published_display": "28 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ)", "summary": "This article provides financial actuals and estimates for 10x Genomics Inc Class A (1KJ) on the Dusseldorf Stock Exchange. It includes analyst opinions on future price targets, historical stock performance, earnings reports, revenue, net income, and employee information. The comp", "url": "https://www.tradingview.com/symbols/DUS-1KJ/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T14:09:35", "published_display": "27 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ)", "summary": "This article provides financial actuals and estimates for 10x Genomics Inc Class A (MUN:1KJ), including income statement, balance sheet, and cash flow data. It covers analyst forecasts, historical price performance, upcoming earnings dates, recent earnings per share and revenue f", "url": "https://www.tradingview.com/symbols/MUN-1KJ/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T11:39:51", "published_display": "26 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of 10x Genomics Inc Class A \u2013 LSE:0A88", "summary": "This article provides financial information for 10x Genomics Inc Class A (LSE:0A88), focusing on its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showcasing the company's financial metrics and data sources.", "url": "https://www.tradingview.com/symbols/LSE-0A88/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:51", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG)", "summary": "This article provides current and historical financial data and analyst estimates for 10x Genomics, Inc. (NASDAQ:TXG). It covers stock price performance, forecasts, market capitalization, earnings, revenue, and other key financial metrics. The company's next earnings report is an", "url": "https://www.tradingview.com/symbols/NASDAQ-TXG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:41:03", "published_display": "26 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of 10x Genomics Inc Class A \u2013 LSE:0A88", "summary": "This article provides the \"Price to sales forward\" metric for 10x Genomics Inc Class A (LSE:0A88). It is a standalone financiero data point without additional analysis or context within the provided content. The relevant financial information is presented as \"Period Value Change ", "url": "https://www.tradingview.com/symbols/LSE-0A88/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:11:10", "published_display": "25 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of 10x Genomics Inc Class A \u2013 LSE:0A88", "summary": "This page from TradingView displays financial information for 10x Genomics Inc Class A (LSE:0A88), specifically focusing on its forward price-to-earnings ratio. The content indicates that while the company's stock is listed on the London Stock Exchange, the market was closed at t", "url": "https://www.tradingview.com/symbols/LSE-0A88/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:11:15", "published_display": "25 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com", "summary": "Serge Saxonov, CEO of 10x Genomics, sold 29,900 shares of company stock for over $1 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock was trading near its 52-week high after a significant gain. The company's stock is currently conside", "url": "https://ng.investing.com/news/stock-market-news/10x-genomics-ceo-serge-saxonov-sells-103m-in-stock-93CH-2573196", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T04:11:10", "published_display": "25 Jun 2026 04:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics CEO Serge Saxonov sells $1.03m in stock", "summary": "Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 29,900 shares of Class A Common Stock worth approximately $1.03 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock traded near its 52-week high, and Mr. Saxonov still holds si", "url": "https://m.uk.investing.com/news/stock-market-news/10x-genomics-ceo-serge-saxonov-sells-103m-in-stock-93CH-4743524?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T03:11:15", "published_display": "25 Jun 2026 03:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan", "summary": "10x Genomics (TXG) CEO Serge Saxonov sold 30,000 shares of Class A common stock on June 22, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales, totaling over $1 million, occurred at weighted average prices between $33 and $36 per share. After ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-537517dfca91.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:09:21", "published_display": "24 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is 10x Genomics (TXG) Stock Soaring Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNcGV3X3EwdllIS0p4cjkzRUYzY3IxTm9VaTd3dTFCY2MzTHBwNm1aVlZiR2tNajZrVzE3THRpdU9iVXZXNVlaeVBYSGtxZ1pmdmdVZHR4NWJsYjhmZWlETTFDUXU2QlZHZjBWYlFMRjJMaS1ib2lpUEItclZ0aVQ2NEdsMHlrNFI4T2VUM2VLSlFEZTdhcEE?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 10X Genomics Inc For: 24 June By Investing.com", "summary": "This article reports on the filing of Form 4 by 10X Genomics Inc. for June 24, as published by Investing.com. It is a brief announcement without further details on the content of the Form 4 filing.", "url": "https://in.investing.com/news/stock-market-news/form-4-10x-genomics-inc-for-24-june-93CH-5469683", "source_name": "Investing.com India", "published_at": "2026-06-23T21:40:57", "published_display": "23 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TXG - 10x Genomics Inc Stock Price and Quote", "summary": "This article provides a detailed stock overview for 10x Genomics Inc (TXG), including its current stock price, financial metrics, analyst ratings, and recent news. It also lists insider transactions, highlighting sales by key executives. The company is involved in life science te", "url": "https://finviz.com/stock?t=TXG", "source_name": "Finviz", "published_at": "2026-06-19T15:11:05", "published_display": "19 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades", "summary": "10x Genomics, Inc. director Shehnaaz Suliman sold a total of 5,723 shares of Class A Common Stock in open-market transactions on June 16, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, at weighted average prices of $32.5890 ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-d2742e1c3306.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:39:33", "published_display": "18 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOS0xkRjIzR2FQaTFQTDlrems1TElfRE5lM0VVclZybjBzSmMzNnkyRWlkOENFUlEzT2pGVzRIZkFkRWtUNHB0UVVLN3p4VWlZUUwtZDFHTGRTZG53QUU4SW4xSHBPbS1xMFVRSDlTdEZxbTdzeThkVWJhZzh0NlNDQi11SEQ4WHhCNEYzYjlxblVzekJKbjh5WHNkWEd6WGZELURSclF0NlNlcmR2TXpCRw?oc=5", "source_name": "TradingView", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Launches Cleveland Clinic Partnership For Bladder Cancer Diagnostics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary", "summary": "TXG (10x Genomics, Inc.) has filed a Form 144 notice detailing proposed sales of Class A Common stock related to multiple RSU vesting events, with JP Morgan Securities LLC identified as an intermediary. The filing specifies various vesting dates between August 2021 and August 202", "url": "https://www.stocktitan.net/sec-filings/TXG/144-10x-genomics-inc-sec-filing-fce261db42c2.html", "source_name": "Stock Titan", "published_at": "2026-06-16T23:58:57", "published_display": "16 Jun 2026 23:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider 10x Genomics (TXG) After Its Recent 187% Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOM0FUcVFpekFRY0E5VWVVZmdwNGU3T1FJdEh1WElYQ2Z6TTJ4aVl2OUR4Nm1ObDJZbjlDTkRUeWpFVzhXTlhxN0kySGdoNm53dGR5QXpiR1JyX2c5YlhjT3NiQjRNa1V5RmZYN0hMamRxRlVxVFZTOVdRQm11MEo5Qmw5NmpBbW5XUUxwc2FEQ1A0eC02Vm42NTZn?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group", "summary": "10x Genomics has acquired Proteintech Genomics, a division specializing in high-plex proteomic solutions for single cell and spatial applications on 10x platforms. This acquisition expands 10x Genomics' capabilities in proteomics and supports its vision for integrating transcript", "url": "https://www.morningstar.com/news/pr-newswire/20260609la79033/10x-genomics-acquires-proteintech-genomics-a-division-within-proteintech-group", "source_name": "Morningstar", "published_at": "2026-06-09T13:00:00", "published_display": "09 Jun 2026 13:00", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) awards 8,829 RSUs to company director", "summary": "10x Genomics director Sarah A. Teichmann was awarded 8,829 restricted stock units (RSUs) of Class A Common Stock. These RSUs were granted at no cash cost and increased her direct holdings to 35,609 shares. The RSUs will vest in quarterly installments, with one-quarter vesting on ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-4368fc47e83d.html", "source_name": "Stock Titan", "published_at": "2026-06-09T09:39:35", "published_display": "09 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs", "summary": "10x Genomics (TXG) director Kimberly J. Popovits was granted 8,829 Restricted Stock Units (RSUs) as an equity award, increasing her direct holdings to 37,445 shares. These RSUs will vest quarterly, starting May 21, 2026, contingent on her continued service. The grant is classifie", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-34557a290421.html", "source_name": "Stock Titan", "published_at": "2026-06-09T09:39:35", "published_display": "09 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) awards 8,829 RSUs to board director", "summary": "10x Genomics director, John R. Stuelpnagel, was granted 8,829 restricted stock units (RSUs). These RSUs will vest in four equal quarterly installments starting May 21, 2026, provided he remains a service provider. Following this grant, Stuelpnagel holds 368,436 shares of Class A ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-4db925ed113a.html", "source_name": "Stock Titan", "published_at": "2026-06-09T09:39:35", "published_display": "09 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) director receives 8,829 RSUs vesting from 2026", "summary": "10x Genomics director Alan Mateo has been granted 8,829 restricted stock units (RSUs) for Class A Common Stock. These RSUs will vest in four equal quarterly installments starting May 21, 2026, contingent upon his continued service. Following this grant, Mateo's direct holdings in", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-04a2f5fbfe19.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:39:35", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings", "summary": "Sridhar Kosaraju, a director at 10x Genomics (TXG), was granted 8,829 Restricted Stock Units (RSUs) as part of a stock-based compensation award. This grant increases his direct holdings to 65,278 shares, with an additional 3,000 shares held indirectly through a family trust. The ", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-7fbd5afbd7c6.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:39:35", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman", "summary": "10x Genomics director Shehnaaz Suliman has been granted 8,829 restricted stock units (RSUs) of Class A Common Stock, as reported in a recent Form 4 filing. This equity award, which has no cash purchase price, increases her direct holdings to 37,445 shares. The RSUs will vest in f", "url": "https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-0d3f6f0ee1e1.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:39:35", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda", "summary": "10x Genomics (NASDAQ: TXG) shareholders approved all proposals at their 2026 annual meeting, including the election of three Class I directors for three-year terms, the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, an", "url": "https://www.stocktitan.net/sec-filings/TXG/8-k-10x-genomics-inc-reports-material-event-1af1ef2dbb13.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:46:32", "published_display": "08 Jun 2026 20:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Stock On Fire: Up 36% With 7-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPU0ZiOWxUVjdwa2pMM3ZwQzZPdE9lRmlSeTRSSlZoU3dqbVFDMmVEX3JyQnJNOUJERUxuQWIwSkQ5SENqNTRfRTJyejNzcXE1bTJNdXFsZ3FiUUdNNExZNHZya3k5X2h0cnNKdlRHVm53NVBDMFI3X2dGc1MxUWxZNHhJNWpXM0ZDQWNWZUtDWW5sMGlzb2QwWkcyTTlMRXhXaWVTakhWdU1zVVhnQlBlUXNaOVp2OFI1Mnc?oc=5", "source_name": "Trefis", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics CEO Serge Saxonov sells $709,057 in shares", "summary": "Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales, conducted between $24.4415 and $24.7092 per share, included shares sold to cover tax obligations and those executed via ", "url": "https://www.investing.com/news/insider-trading-news/10x-genomics-ceo-serge-saxonov-sells-709057-in-shares-93CH-4713355", "source_name": "Investing.com", "published_at": "2026-05-30T08:10:53", "published_display": "30 May 2026 08:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics CEO Serge Saxonov sells $709,057 in shares By Investing.com", "summary": "Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales were related to tax obligations from restricted stock units and a pre-arranged trading plan. Despite his sales, Saxonov r", "url": "https://ng.investing.com/news/insider-trading-news/10x-genomics-ceo-serge-saxonov-sells-709057-in-shares-93CH-2532354", "source_name": "Investing.com Nigeria", "published_at": "2026-05-28T22:39:37", "published_display": "28 May 2026 22:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x genomics president Hindson sells $283,399 in company stock By Investing.com", "summary": "10x Genomics President and Chief Scientific Officer, Benjamin J. Hindson, sold 11,595 shares of company stock totaling $283,399 to cover tax obligations. This sale occurred while TXG stock was trading near its 52-week high after a significant 197% gain, though it appears overvalu", "url": "https://au.investing.com/news/insider-trading-news/10x-genomics-president-hindson-sells-283399-in-company-stock-93CH-4459010", "source_name": "Investing.com Australia", "published_at": "2026-05-28T08:02:00", "published_display": "28 May 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess 10x Genomics (TXG) After Its 188% One Year Share Price Surge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNdFB6OWxld3B1ZnNPTkVqRzNUem9zS0o1THlyZ1A2OVVhYjEzY0lTMjdQdkFIcGxxT0FoY21xLTVWamsyRXBycG1EbkJzWERBV1pnRDA1b2tPUVZqWmRESGp0b1VBWTFDUzVzT3d3SVZzNVJNakd1MlFqSXIzSDU1UE9n?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At 10x Genomics (TXG) Valuation After A Strong Year And Recent Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZWcwc0ZhY2pRc25US0I1XzNLWi1GQ0lJN3BEdWZHd2k2ZTJxbWMtOF9FQ0t2MThjMERCNXRkTUc0VlFOa0tmYjVaYmZWMVBZdmtYNlBwUjYySE9LYnNKX2ZtWkFuRDZpRk9mWjNBUERaTnJyX05yOTBXRFlRbGNsRllRbnV0LTJQWC1UZ0dmU2tLek90MDlHcUNVZWE?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why 10x Genomics (TXG) Stock Is Down Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNVGVkaDZ2emhIXzdrM1ZLRDBHYjhqV3d2ZUNYcUxVUFpDcDEwUTBJV2Y5dWtRSnhIRmxiYXhiSTlVYzVFczRsWDdhblh4TmRZYkVGX3RKQVJ4X252Wl9OMEtxZTNBbmRJLXh0V1NMa3NpNWYzOHA5NHFnaHUyWlk0aHRKLWdQTGhLeTRSZy1kTzFSVEFGRTdVbW84ampxcUlZLUFR?oc=5", "source_name": "StockStory", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Loss Reduction To US$0.35 TTM EPS Challenges Bearish Profitability Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQaFMzZHFoQk9EcEpxQUZzOUhxVFBIaHc1MzQwOTA0SjMxWnkwYmZsNGdEdEQxOEkwZVh6MGI0OGdFMW8tV1JIeDRzcVBERlU2ZlRrV21CeXVXd281Qm0ySGxtNW9Jcm5GNWxxV1dURDB0WDF2elVhZVhuVVNCMklKVndUMERLWXpDTnRFVWstclBuaHRpbkpEbDcwM1JSTFFzaFBLNllTY1ZwUzRONUpCMnZQcWgzdDA3NHdjaXNtME5SbTNheElqYm92OHd0Mk52VGZaNVZUOVExOUdv0gHiAUFVX3lxTE1nd1gxNmplZGh0bWE2Tk5uaWpkWVFVMGNDLUJvR05zSHFXbEZieDA0bllrNVNyNTZlbzVUN2xEUVFHT05fekV4WFVXazY5ZlQ3TXJicDZwX2FsaWpZb2ZGVGR1REdRWE5fbWJfR3F5YWdQNHYtSGZwbzFzQXBDMi1uWVBVWksxLU0tZkZBWmtwcGVvZFpQTk44eUtFUFRFZWRvSk5qSVBUc09SR3JpbWZfWks1U0YwWFlYU29BR2VkQkIySFNGTFJ0WEJrMTZqNE5XWXpQUk05QnlBbEFhS2FnR2c?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOWGxlcFNXa2ZTaE5DVm9IMGo1VFdPN2tCTHU1YkVKV3NmQWVUMkZnZnc1bFZHZHBGVE8tZVhkYWpNek9EbHBydGZHWk55YnBFU25QTU1sd1VnQVBJdnpwaUo4MlVpaFAyd2g1NVk1NWk2cjlFLWNWck5VbVpOUU80Uld4NjdLQ3REQm1JTjl1QnZWeWFCN1FhX3pEdmZGSHZDc2MxZUtsejJiek9SNnJiU2NUYw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPN1NiQzVablpIaENaM3ZTdEVLTi1ZYnlUeTZNNm1kQVpTa3VMS3dqX1dzSXlZNVBfUXA2NlZqaEZOREpVNWJLS05iX1pGWlRDMFMwNW1DQVlLSmk1TXJJaDh3c2FfQzV6UXFXT3IyajdJSVNrMm02SzBUZGtNdWdTakxvbFVJRVY5bmFJYWtMTFFzYlIxcFd2RnJuTQ?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Stock Falls 5.4% After Thermo Fisher Q1 Miss Signals Life Sciences Slowdown - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNVklBLVYtY2J2QXlHTlpLSm9ZdHRpOWVsSHlVeFNUeEVobHQ1TmFibW1DRU83UHczclozQ2wtOEVMOE4wLTl4UFZGMEFJbDNsX1haRTUxLWRMc3FDRm9RZ2syaXR1NS1IdDdSeC1ma1JaOUg4eW15VFRkemNHS2NXcjQ2OFplWXVYZ25MdnYyYTdzZThTdHc?oc=5", "source_name": "IndexBox", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 6, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why 10x Genomics (TXG) Shares Are Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQOS1EUXFGeThJbTNvcmEtRS1GRjBJTGhuMGx2QmhXbFdtRmZjbUduQVktR2MxSTZjaE9TMGVIX1VfOFh6SGM1SUVGenZGQ0F3OXZiV3kzaWRzOWV1VExydFF2cjJuOVVDX3I5Sm9mQnY0M3JjdVVXYlJGUWNMRXcwalNFR21TLVVnNy0tSlBCSU5IUVhuUHB3?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics (TXG) Launches Atera: A Breakthrough in Spatial Bio", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOQjkwRWxrODdYelF1RnY1TXJyb3JFTUozc0o3ai11NkQtNHBma1N6U1dNUzdDVU55dk9sRjRpSjZHaVdZUWhVMXlzamJ3cmZBNGlNaDFtMER3cHR3VWxFUFhCbEkzbl9RajBjRU4yYnRrWXJMWXUwTDlyeHVGTGhKM3dTRnJCdzl6bFlqbEVuQWdSTm9RSmZvUE5UcE5PaGtySmVFaVdHWQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Overvalued Tech Stocks? Texas Instruments, Jabil, 10x Genomics Face Scrutiny - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPVXB0SGxNbVZpblAxMjY0YUIzMlBVUU1YdFFPTGRZdHFQaWt4NUtrRnY1VVI5TWtMdUppZjcwTXFBVTZ2YnF5c1hOZEpoVGJicE5yenRUU3FlMTZKeERpQUstNFlja3RxVzRQTzdKZGVNVGpHS0Y1TlphOUI1UUEwYUxRWk1KV2hKclJteHI4MVNFaEdn?oc=5", "source_name": "IndexBox", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioptimus launches spatial biology atlas with 10x Genomics", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPWmFtWjY4YXFoM29icnV5YXdBSzB3YVdmc1E5bmI0T3k1U19oR1FVSzNzWlNQYmJFOGtEaC1HVUx6dnlIMjBkOU1kNS1aZGlqY0puSDl6ZnhTd25VS2JjSTUwbktTLWE2MFBrWHYyTzcxX204X0IydnN3NXNUQnEyN3owYW9KQ1luU3dWQ2NEbkhiSmthY05CdFoza1l2djkzeWJoVlpBWmFUNGVOTWRoV3JoMGxtZw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNZXpuV2xhcENqNm1FS00xSXAxUGRTUm9mTEs0OGFvLVhaWHdWQmZPTlltTkQ2QUlnVDRRbG5fa0ZIa20wZW9HZi1haTZ2YU9NWlJDaFBxYWtkOTdqLTk3Z1AtV1RhVmdEczFfbDNXSXgwRlg4NWM0X09DaS0ta3NnMUNKYk5SVUtuX0d0bWVfeTRzVGFmUnUzSDNlTDJuanlzVHBsMnJFUi1BUmw5UTdqWFh6ME4xR1lZUGJBS0QtbU94Y2NqVjhCSjJqTjRraVJDdldPUDcxQThiNk5XYUpITzl2SGtuYk0yOG91TDJ1NA?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 112, "total_relevant": 61, "sentiment_summary": {"positive": 12, "negative": 8, "neutral": 41, "score": 52, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 10.45, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.45, "count": 2}], "positive_events": 12, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 42.73, "latest_week": "2026-07-10", "one_week_move": 9.5, "four_week_move": 48.2, "twelve_week_move": 63.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.765573, "market_dynamics_buy_signal": false, "relative_strength": 90.065531, "fair_value_gap": 73.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.9279, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.5% over one week, +48.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 9}, {"label": "simplywall.st", "count": 7}, {"label": "PR Newswire", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "StockStory", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 61}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "61", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+9.5% over one week, +48.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026"}], "updated_at": "2026-07-16T06:03:56.344885+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}